Processing speed drops after medulloblastoma diagnosis

September 5, 2013

Processing speed drops after medulloblastoma diagnosis
Among key cognitive functions, processing speed shows the poorest outcomes five years after diagnosis of pediatric medulloblastoma, according to a study published online Aug. 26 in the Journal of Clinical Oncology.
(HealthDay)—Among key cognitive functions, processing speed (PS) shows the poorest outcomes five years after diagnosis of pediatric medulloblastoma, according to a study published online Aug. 26 in the Journal of Clinical Oncology.

To investigate cognitive functions of pediatric patients diagnosed with medulloblastoma, Shawna L. Palmer, Ph.D., from St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues included 126 patients (aged 3 to 21 years at diagnosis) enrolled onto a collaborative protocol for medulloblastoma. Treatment included postsurgical risk-adapted craniospinal irradiation (high risk [HR], 36 patients; average risk, 90 patients) followed by four cycles of high-dose chemotherapy with stem-cell support. A median of three neuropsychological evaluations per patient were performed over a five-year period using the Woodcock-Johnson Tests of Cognitive Abilities Third Edition.

The researchers found that there was a significant association for younger age at diagnosis, HR classification, and higher baseline scores with poorer outcomes in PS. There were less in broad attention (BA) and (WM) over time among patients treated as HR and those with higher baseline scores. There were significant associations for parent education and marital status with BA and WM baseline scores, but not changes over time.

"Identifying cognitive domains most vulnerable to decline should guide researchers who are aiming to develop efficacious cognitive intervention and rehabilitation programs, thereby improving the quality of survivorship for the pediatric population," the authors write.

Explore further: Social outcomes good for most pediatric brain tumor survivors

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Social outcomes good for most pediatric brain tumor survivors

October 21, 2012
(HealthDay)—While the majority of survivors of pediatric embryonal tumors display positive social outcomes several years after diagnosis and treatment, specific risk factors may affect social adjustment and behavior over ...

Spondylolisthesis sx improves pediatric health related-QOL

July 30, 2013
(HealthDay)—In pediatric patients with high-grade spondylolisthesis, health-related quality of life (HRQOL) improves significantly after surgery, especially in patients with low baseline HRQOL scores, according to a study ...

Simple urine test may help identify individuals with diabetes at risk for cognitive decline

August 29, 2013
The presence of protein in the urine may be a marker of risk for future cognitive decline in patients with type 2 diabetes and normal kidney function, according to a study appearing in an upcoming issue of the Clinical Journal ...

Mild cognitive decline in nearly half lacunar stroke patients

August 27, 2012
(HealthDay)—Mild cognitive impairment (MCI) is present in nearly half of patients with lacunar stroke, according to a study published online Aug. 18 in the Annals of Neurology.

Accelerated cognitive decline seen with T2DM in middle age

January 21, 2013
(HealthDay)—Middle-aged patients with type 2 diabetes show accelerated cognitive decline in information processing speed and executive function, according to a study published online Dec. 28 in Diabetes Care.

Mild cognitive impairment at Parkinson's disease diagnosis linked with higher risk for early dementia

March 25, 2013
Mild cognitive impairment at the time of Parkinson disease (PD) diagnosis appears to be associated with an increased risk for early dementia in a Norwegian study, according to a report published Online First by JAMA Neurology.

Recommended for you

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.